Intuitive Surgical stock trades 0.02 percent above its Xetra close
π Intuitive Surgical stock traded at EUR 378.93 on October 10, 2026, showing a slight 0.02 percent gain over the previous close.
π Worldwide procedures for Intuitive Surgical grew 16 percent year over year in the second quarter of 2026 according to Zacks Research.
π¬ Ion procedures specifically saw nearly 36 percent growth, while Da Vinci procedures rose almost 15 percent during the same period.
π° The company reported a robust second-quarter revenue of USD 2.89 billion.
π Zacks assigned Intuitive Surgical a No. 2 Buy rank following the release of its strong quarterly performance data.
π The next Xetra trading session for Intuitive Surgical is scheduled to open on October 12, 2026.
Bullish Signals
- Worldwide procedures grew 16 percent year over year in the second quarter of 2026, demonstrating strong demand for the company's surgical systems.
- Ion procedures experienced nearly 36 percent growth, highlighting successful expansion into new robotic technology segments.
- Da Vinci procedures rose almost 15 percent, reinforcing the core business unit's continued market dominance and adoption.
- The company achieved a second-quarter revenue of USD 2.89 billion, reflecting solid top-line execution.
- Zacks Research upgraded or maintained a positive outlook by assigning Intuitive Surgical a No. 2 Buy rank based on recent financial figures.
Full Analysis
Intuitive Surgical stock traded at EUR 378.93 on October 10, 2026, representing a marginal 0.02 percent increase from the previous Xetra close of EUR 378.85. Weekend trading activity at Lang & Schwarz showed prices ranging between EUR 360.28 and the session high of EUR 378.93, with the market anticipating the next trading session scheduled for October 12, 2026.
Zacks Research published a report on October 6, 2026, highlighting significant growth in Intuitive Surgical's worldwide procedures during the second quarter of 2026. The data indicates that worldwide procedures grew by 16 percent year over year, with specific gains for Da Vinci procedures rising nearly 15 percent and Ion procedures surging almost 36 percent.
Financial performance metrics cited in the report include a second-quarter revenue of USD 2.89 billion. Based on these strong operational results, Zacks assigned Intuitive Surgical a No. 2 Buy rank, signaling positive analyst sentiment regarding the company's market position and growth trajectory in the surgical robotics sector.